0001171000-15-000106.txt : 20151124
0001171000-15-000106.hdr.sgml : 20151124
20151124151257
ACCESSION NUMBER: 0001171000-15-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151123
FILED AS OF DATE: 20151124
DATE AS OF CHANGE: 20151124
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heffernan Mark
CENTRAL INDEX KEY: 0001632439
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 151252475
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-11-23
0001618561
Nexvet Biopharma plc
NVET
0001632439
Heffernan Mark
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK,RAHAN ROAD
TULLAMORE , CO. OFFALY
L2
R35 FR98
IRELAND
0
1
0
0
Chief Executive Officer
Ordinary Shares
2015-11-23
4
M
0
7250
.125
A
19334
D
Ordinary Shares
243587
I
By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>
Option to Purchase Shares
.125
2015-11-23
4
M
0
7250
0
D
2020-11-05
Ordinary Shares
7250
9666
I
By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>
The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
7,250 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 4,833 options to purchase shares will vest and become exercisable on each of 7/1/16 and 7/1/17.
/s/ Mark Heffernan by Geraldine T. Farrell, Attorney-in-Fact
2015-11-23